CVS Caremark Corporation Announces Consent Solicitation Relating to Its 6.125% Senior Notes Due August 15, 2016 (CUSIP NO. 126650BE9)
WOONSOCKET, R.I., Aug. 9, 2011 /PRNewswire via COMTEX/ --
CVS Caremark Corporation (NYSE: CVS) announced today that it is soliciting consents (the "Consent Solicitation") from the registered holders as of 5:00 p.m., New York City time on August 8, 2011 (the "Record Date") of its 6.125% Senior Notes due August 15, 2016 (the "Notes") to terminate the replacement capital covenant, which was entered into on May 25, 2007, for the benefit of the holders of the Notes in connection with the issuance of its 6.302% Enhanced Capital Advantaged Preferred Securities due 2062 (the "ECAPS"). Under the replacement capital covenant, CVS Caremark is prohibited from repurchasing, redeeming or repaying its ECAPS on or before June 1, 2047 unless a specified portion of the funds used to repay, redeem or repurchase the ECAPS are obtained by CVS Caremark through the sale of common stock or certain other equity or equity-like securities. The termination of the replacement capital covenant requires the consent of the holders of a majority in aggregate principal amount of the outstanding Notes (the "Requisite Consents").
CVS Caremark will make a cash payment to each holder of the Notes of $15.00 per $1,000 in principal amount of the Notes as to which a duly executed consent is delivered and not revoked on or prior to the expiration of the Consent Solicitation if the consent solicitation is successful and the replacement capital covenant is terminated. Consents may be revoked at any time up to the earlier of 5:00 p.m., New York City time, on August 22, 2011 and the time and date on which CVS Caremark receives the Requisite Consents. Any consent payment due will be paid promptly after the expiration of the Consent Solicitation and termination of the replacement capital covenant. The Consent Solicitation will expire at 5:00 p.m., New York City time, on August 22, 2011, unless terminated or extended by CVS Caremark in its sole discretion. The Consent Solicitation is being made pursuant to a "Consent Solicitation Statement" dated today, which sets forth a more comprehensive description of the terms of the Consent Solicitation. This press release is not a solicitation of consents to the proposed termination of the replacement capital covenant.
Copies of the Consent Solicitation Statement and the consent form may be obtained by holders of the Notes from the Information and Tabulation Agent for the Consent Solicitation, D.F. King & Co., Inc., at (800) 949-2583 (toll-free).
Barclays Capital Inc. and RBS Securities Inc. are the Solicitation Agents for the Consent Solicitation. Questions may be directed to Barclays Capital Inc., at (800) 438-3242 (toll-free) or (212) 528-7581 (collect) or RBS Securities Inc., at (877) 297-9832 (toll-free) or (203) 897-4825 (collect).
About the Company:
CVS Caremark is the largest pharmacy health care provider in the United States with integrated offerings across the entire spectrum of pharmacy care. We are uniquely positioned to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of approximately 65,000 pharmacies, including more than 7,300 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical offerings include our signature Pharmacy Advisor(TM) program as well as innovative generic step therapy and genetic benefit management programs that promote more cost effective and healthier behaviors and improve health care outcomes. General information about CVS Caremark is available through the Company's website at http://info.cvscaremark.com/.
This press release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company strongly recommends that you become familiar with the specific risks and uncertainties outlined under the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2010 and under the section entitled "Cautionary Statement Concerning Forward-Looking Statements" in our most recently filed Quarterly Report on Form 10-Q.
SOURCE CVS Caremark Corporation